Last updated: 15 August 2024 at 4:03pm EST

Erin Burkhart Net Worth




The estimated Net Worth of Erin Burkhart is at least $1.49 Million dollars as of 13 August 2024. Erin Burkhart owns over 714 units of Biomarin Pharmaceutical stock worth over $1,224,986 and over the last 3 years Erin sold BMRN stock worth over $270,000.

Erin Burkhart BMRN stock SEC Form 4 insiders trading

Erin has made over 2 trades of the Biomarin Pharmaceutical stock since 2024, according to the Form 4 filled with the SEC. Most recently Erin sold 714 units of BMRN stock worth $64,260 on 13 August 2024.

The largest trade Erin's ever made was selling 2,286 units of Biomarin Pharmaceutical stock on 10 April 2024 worth over $205,740. On average, Erin trades about 429 units every 18 days since 2022. As of 13 August 2024 Erin still owns at least 14,449 units of Biomarin Pharmaceutical stock.

You can see the complete history of Erin Burkhart stock trades at the bottom of the page.



What's Erin Burkhart's mailing address?

Erin's mailing address filed with the SEC is C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO STREEET, SAN RAFAEL, CA, 94901.

Insiders trading at Biomarin Pharmaceutical

Over the last 21 years, insiders at Biomarin Pharmaceutical have traded over $153,109,113 worth of Biomarin Pharmaceutical stock and bought 151,118 units worth $2,557,509 . The most active insiders traders include Jean Jacques Bienaime, Mark J Enyedy, and Kathryn E Falberg. On average, Biomarin Pharmaceutical executives and independent directors trade stock every 8 days with the average trade being worth of $912,996. The most recent stock trade was executed by Erin Burkhart on 13 August 2024, trading 714 units of BMRN stock currently worth $64,260.



What does Biomarin Pharmaceutical do?

biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment



What does Biomarin Pharmaceutical's logo look like?

Biomarin Pharmaceutical Inc. logo

Complete history of Erin Burkhart stock trades at Biomarin Pharmaceutical

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
13 Aug 2024 Erin Burkhart
GVP and Chief Accounting Officer
Sale 714 $90.00 $64,260
13 Aug 2024
14,449
10 Apr 2024 Erin Burkhart
GVP and Chief Accounting Officer
Sale 2,286 $90.00 $205,740
10 Apr 2024
16,156


Biomarin Pharmaceutical executives and stock owners

Biomarin Pharmaceutical executives and other stock owners filed with the SEC include: